Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of IDE196 in combination with crizotinib in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.

X
Trial Profile

A phase 1 study of IDE196 in combination with crizotinib in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizotinib (Primary) ; Darovasertib (Primary)
  • Indications Colorectal cancer; Lung cancer; Malignant melanoma; Solid tumours; Uveal melanoma
  • Focus Adverse reactions
  • Sponsors IDEAYA Biosciences
  • Most Recent Events

    • 10 Jan 2022 According to an IDEAYA Biosciences media release, company is targeting update of clinical data and regulatory guidance on potential registrational clinical trial in first half 2022
    • 05 Jan 2021 According to an IDEAYA Biosciences media release, first patient has been dosed in this study.
    • 05 Jan 2021 Status changed from planning to recruiting, according to an IDEAYA Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top